Stock ATYR ATYR PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News aTyr Pharma, Inc.

Equities

ATYR

US0021202025

Real-time Estimate Cboe BZX
Other stock markets
 03:50:33 2024-06-10 pm EDT 		5-day change 1st Jan Change
1.98 USD 0.00% Intraday chart for aTyr Pharma, Inc. +8.65% +42.55%
Jun. 05 ATyr Pharma, Inc. will Change its Ticker to ATYR. from LIFE CI
May. 14 ATyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT? Study in Pulmonary Sarcoidosis CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ATyr Pharma, Inc. will Change its Ticker to ATYR. from LIFE
CI
ATyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
AQ
ATyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
ATyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
AQ
ATyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
AQ
ATyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT? Study in Pulmonary Sarcoidosis
CI
ATyr Pharma to Present at Upcoming Investor Conferences
AQ
Atyr Pharma: Q1 Earnings Snapshot
AQ
ATyr Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (LIFE) ATYR PHARMA Reports Q1 Revenue $235,000
MT
ATyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
AQ
ATyr Pharma to Participate in April Investor Conferences
AQ
RBC Cuts Price Target on aTyr Pharma to $16 From $19, Keeps Outperform Rating, Speculative Risk Qualifier
MT
Transcript : ATyr Pharma, Inc., Q4 2023 Earnings Call, Mar 14, 2024
ATyr Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Atyr Pharma: Q4 Earnings Snapshot
AQ
ATyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
AQ
ATyr Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
ATyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
AQ
ATyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATYR Stock
  4. News aTyr Pharma, Inc.